The results showed that curcumin downregulated the expression of FEN1 in a dose-dependent manner both in vitro and in vivo, suggesting that FEN1 could be a potential therapeutic target to alleviate cisplatin resistance in breast cancer. Here, FEN1 is linked to breast carcinoma.